ADC药物联合免疫治疗在膀胱癌的应用
Application of ADC and immunotherapy in bladder cancer
邢金春 1赵仲杰 1刘正升1
作者信息
- 1. 厦门大学附属第一医院泌尿外科(福建厦门,361003)
- 折叠
摘要
膀胱癌(bladder cancer,BCa)是一种常见的泌尿系恶性肿瘤,以尿路上皮癌最常见.长期以来,都以化疗为主,尽管有多种治疗方式,但一些患者会出现疾病复发和转移,总体预后不良,长期生存率低.抗体-药物偶联物(antibody-drug conjugates,ADC)结合了抗体药物的靶向能力和化疗药物的细胞毒性,最近已成为个体化精准癌症治疗发展的一个突出研究重点.目前,基于ADC的联合疗法,特别是ADC联合免疫检查点抑制剂(immune checkpoint inhibitors,ICIs),已经显示出可喜的疗效.这种联合方法推进了 BCa的治疗,显示出未来成为晚期BCa标准一线治疗的潜力.因此,本文对免疫联合ADC药物治疗BCa作一述评.
Abstract
Bladder cancer(BCa)is a common malignant tumor of the urinary system,and urothelial carcino-ma is the most common type.Although there are multiple treatment options,including surgery,chemotherapy,and immune checkpoint inhibitors(ICIs),some patients suffer from disease recurrence and metastasis,resulting in unfavorable prognosis and dismal long-term survival rates.Antibody-drug conjugates(ADC),which combine the targeting ability of antibody drugs and the cytotoxicity of chemotherapy drugs,have recently become a promi-nent research focus in the development of individualized precision cancer treatment.Currently,ADC-based combi-nation therapy,especially combined with ICIs,has shown promising therapeutic effects.This combined approach has advanced the treatment of BCa,demonstrating the potential for becoming a standard first-line treatment for advanced BCa in the future.Therefore,this article offers a review of the latest research of this field.
关键词
膀胱癌/ADC药物/新辅助治疗/免疫治疗Key words
bladder cancer/antibody-drug conjugates/neoadjuvant therapy/immunotherapy引用本文复制引用
出版年
2024
NETL
NSTL
万方数据